The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth

被引:38
|
作者
Montgomery, Elizabeth T. [1 ]
Atujuna, Millicent [2 ]
Krogstad, Emily [1 ]
Hartmann, Miriam [1 ]
Ndwayana, Sheily [2 ]
O'Rourke, Shannon [1 ]
Bekker, Linda-Gail [2 ]
van der Straten, Ariane [1 ,3 ]
Minnis, Alexandra M. [1 ,4 ]
机构
[1] RTI Int, Ctr Global Hlth SSES, Womens Global Hlth Imperat, San Francisco Project Off, San Francisco, CA USA
[2] Desmond Tutu HIV Res Ctr, Cape Town, South Africa
[3] Univ Calif San Francisco, Ctr AIDS Prevent Studies, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
关键词
South Africa; youth; PrEP; sustained-release long-acting PrEP; implants; injections; DAPIVIRINE VAGINAL RING; PREVENTION; ACCEPTABILITY; TRIAL;
D O I
10.1097/QAI.0000000000001960
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. Methods: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. Results: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. Conclusions: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 50 条
  • [31] What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?
    Mohareb, Amir M.
    Kouame, Menan Gerard
    Nouaman, Marcellin
    Kim, Arthur Y.
    Larmarange, Joseph
    Neilan, Anne M.
    Lacombe, Karine
    Freedberg, Kenneth A.
    Boyd, Anders
    Coffie, Patrick
    Hyle, Emily P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 (03)
  • [32] Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
    Gunawardana, Manjula
    Remedios-Chan, Mariana
    Sanchez, Debbie
    Fanter, Rob
    Webster, Simon
    Webster, Paul
    Moss, John A.
    Trinh, MyMy
    Beliveau, Martin
    Ramirez, Christina M.
    Marzinke, Mark A.
    Kuo, Joseph
    Gallay, Philippe A.
    Baum, Marc M.
    PHARMACEUTICAL RESEARCH, 2023, 40 (07) : 1657 - 1672
  • [33] A Mixed Methods Evaluation of Pharmacists' Readiness to Provide Long-Acting Injectable HIV Pre-exposure Prophylaxis in California
    Beltran, Raiza M.
    Hunter, Lauren A.
    Packel, Laura J.
    De Martini, Loriann
    Holloway, Ian W.
    Dong, Betty J.
    Lam, Jerika
    Mccoy, Sandra I.
    Ochoa, Ayako Miyashita
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 97 (02) : 142 - 149
  • [34] Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study
    van Vliet, Marjolein M.
    Hendrickson, Cheryl
    Nichols, Brooke E.
    Boucher, Charles A. B.
    Peters, Remco P. H.
    van de Vijver, David A. M. C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 (12)
  • [35] Gender norms, HIV risk, and attitudes towards pre-exposure prophylaxis and other HIV preventive interventions among South African adolescents
    Agaku, Israel
    Nkosi, Lungile
    Gwar, Joy
    Tsafa, Tina
    PAN AFRICAN MEDICAL JOURNAL, 2022, 41
  • [36] Barriers to HIV pre-exposure prophylaxis among African, Caribbean and Black men in Toronto, Canada
    Zhabokritsky, Alice
    Nelson, LaRon E.
    Tharao, Wangari
    Husbands, Winston
    Sa, Ting
    Zhang, Nanhua
    Thomas-Pavanel, Jamie
    Baidoobonso, Shamara
    Kaul, Rupert
    PLOS ONE, 2019, 14 (03):
  • [37] Brief communication: attitudes and preferences of long-acting injectable HIV preexposure prophylaxis among Thai adolescents and young adults
    Wongsethanatada, Alisa
    Songtaweesin, Wipaporn Natalie
    Wongharn, Prissana
    Moonwong, Juthamanee
    Khamthi, Sasiprapha
    Pitikawinwong, Lucksanapon
    Puthanakit, Thanyawee
    AIDS RESEARCH AND THERAPY, 2025, 22 (01):
  • [38] Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment
    Dlamini, Wendy W.
    Mirembe, Brenda G.
    Krows, Meighan L.
    Peacock, Sue
    Kotze, Philip L.
    Selepe, Pearl
    Smit, Jenni
    Mandona, Nelly
    Louw, Cheryl
    Nuwagaba-Biribonwoha, Harriet
    Omollo, Victor O.
    Zwane, Zinhle
    Panchia, Ravindre
    Mwelase, Noluthando
    Senne, Melissa
    Naidoo, Logashvari
    Chihana, Rachel
    Delany-Moretlwe, Sinead
    Gill, Katherine
    Macdonald, Pippa
    van Heerden, Alastair
    Bosman, Shannon
    Peters, Remco P. H.
    du Preez, Philip
    Ward, Amy
    Celum, Connie
    Heffron, Renee
    Velloza, Jennifer
    INSIGHT Study Team
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2025, 28 (02)
  • [39] The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women
    Walensky, Rochelle P.
    Park, Ji-Eun
    Wood, Robin
    Freedberg, Kenneth A.
    Scott, Callie A.
    Bekker, Linda-Gail
    Losina, Elena
    Mayer, Kenneth H.
    Seage, George R., III
    Paltiel, A. David
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (10) : 1504 - 1513
  • [40] Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)
    Rael, Christine Tagliaferri
    Lopez-Rios, Javier
    McKenna, Stacey A.
    Das, Doyel
    Dolezal, Curtis
    Abascal, Elena
    Carballo-Dieguez, Alex
    Schnall, Rebecca
    Hope, Thomas J.
    Bauermeister, Jose
    Bockting, Walter
    AIDS AND BEHAVIOR, 2021, 25 (12) : 4180 - 4192